ClinicalTrials.gg
RecruitingNCT07138560BOOST-PDUpdated Oct 15, 2026

BOOST-PD A Naturalistic Study on IPX-203 for Parkinson's Disease

A Phase 4 interventional study of CREXONT ER in Parkinson Disease, sponsored by The Cleveland Clinic. Recruiting at 1 site in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by The Cleveland Clinic · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 3 months later.
Updated Oct 15, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
22
Allocation
Not applicable
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Parkinson Disease by The Cleveland Clinic — 5 open to participants now, 5 under way, none of them phase 3. Parkinson Disease · The Cleveland Clinic.

Planned enrollment
11th of 14
22 · median 38
Started
2025
with 1 other
Phase 4
Only one
of the 15
Registered
11th of 15
by date

Among the 15 studies in Parkinson Disease by The Cleveland Clinic, this one is the 11th largest by planned enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2025, is the only one in phase 4, and was the 11th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

5 of the 15 studies in Parkinson Disease by The Cleveland Clinic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Parkinson Disease by The Cleveland Clinic, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the effect of IPX203 (Crexont®) - the newest extended-release levodopa formulation - on the duration and quality of good on time, using a wearable device to monitor symptoms. 'Good on time' refers to a period (minutes to hours) when a patient experiences optimal symptom control due to effective medication and has better overall functioning without troublesome dyskinesias. The change in the duration and quality of on-time will be measured by a wearable device placed on your wrist called KinesiaU.

Read the detailed description

This research is being done because a new, longer-duration formulation of levodopa named IPX203 (brand name: Crexont®) has been recently approved by the FDA. The pivotal study on this drug demonstrated that IPX203 significantly increased the daily good on-time compared to immediate release carbidopa-levodopa (IR CD-LD), where good on-time is the time when the Parkinson's symptoms are improved without troublesome dyskinesias. In that study, the participants were taking IPX203 a mean of 3 times per day which still left a mean of 4.18 hours of off-time per day (when symptoms returned). These data were based on diaries filled out by the participants.

The aim of the study is to expand the current knowledge on IPX203, analyzing the changes in good on-time after careful and tailored adjustments, as in the real-world setting. This will be done with the assistance of a wearable device to obtain objective data. Additional variables such as changes in the tremor scores, conversion from other drugs such as Rytary and COMT inhibitors, and the difference between starting and final IPX203 doses will be evaluated.

03

Conditions studied

  • Parkinson Disease

Browse trials for

Keywords

  • Crexont
  • motor fluctuations
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • - Participant is 40 years or older
  • Diagnosed with idiopathic Parkinson's disease and is deemed to be levodopa responsive
  • Baseline MDS-UPDRS score in OFF-state is > 20
  • Patient is being treated with a stable regimen of CD-LD for at least four weeks
  • The minimum most frequent levodopa dosing is 100 mg if using IR CD-LD and 195mg if using Rytary; maximum levodopa dosing per day is 1200 mg if using IR CD-LD, 1000 mg if associated with a COMT inhibitor, and 2400 mg if using Rytary
  • Participant can be on stable doses of any levodopa adjunctive medications and/or psychotropic medications for at least 30 days
  • Participant experiences off time estimated at 2 hours or more per day; participant can comply with the wearable kinematic device.

Exclusion criteria

Exclusion Criteria:

  • - Participants with severe dyskinesia as defined by a score of 4 on Question 4.1 (time spent with dyskinesia) of UPDRS IV
  • Currently on device-aided therapies for advanced PD
  • Using controlled-release CD-LD apart from a single daily bedtime dose
  • Using "on demand" therapy unless willing to stop it during the study period
  • Have a diagnosis hypothesis of dopamine dysregulation syndrome or evidence of significant levodopa-related complications including orthostatic hypotension or psychosis
  • History of dementia or MOCA score lower than 23
  • Significant medical history might interfere significantly with study participation
  • Being enrolled in other clinical trials involving active medication interventions.
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
22 participants (estimated)

Study arms

  • Other
    Intervention Arm

    The intervention arm will be patients converting to shorter dose intervals of Crexont (IPX203) and allowing for higher dosing frequency, as practiced in real-world settings, combined with objective monitoring of on-time periods and other parameters using the KinesiaU device, could reveal additional benefits of Crexont (IPX203) treatment.

    Drug: CREXONT ER

Interventions

  • DrugIPX203Studies of IPX203IPX203 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    exploring shorter dose intervals of Crexont (IPX203) and allowing for higher dosing frequency, as practiced in real-world settings, combined with objective monitoring of on-time periods

    Also known as: IPX203

06

What researchers measure

Primary outcomes

  1. Primary Endpoint

    Mean change in the average duration of good on-time from baseline to end of study

    Time frame: 8 weeks

Secondary outcomes

  1. Secondary Endpoint

    Mean change in the average 'slowness' scores as measured by KinesiaU

    Time frame: 8 weeks

  2. Secondary Endpoint

    Mean change in time spent with tremor as measured by KinesiaU

    Time frame: 8 weeks

  3. Secondary Endpoint

    Mean change in the average tremor scores as measured by KinesiaU

    Time frame: 8 weeks

  4. Secondary Endpoint

    Mean change in time spent with dyskinesia as measured by KinesiaU

    Time frame: 8 weeks

  5. Secondary Endpoint

    Mean change in the continuous on time as measured by KinesiaU

    Time frame: 8 weeks

Other outcomes

  1. Exploratory Endpoints

    Mean difference between KinesiaU and PD diary measurements of change in good on-time from baseline to end of study

    Time frame: 8 weeks

  2. Exploratory Endpoint

    Difference in the Patient Global Impression of Change from baseline to end of study.

    Time frame: 8 weeks

  3. Exploratory Endpoint

    Difference between Non-Motor Fluctuation Assessment Questionnaire from baseline to end of study.

    Time frame: 8 weeks

  4. Exploratory Endpoint

    The average time (in weeks) taken to reach the final dose.

    Time frame: 8 weeks

  5. Exploratory Endpoint

    The average number of adjustments needed to reach the final dose.

    Time frame: 8 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Modi NB, Mittur A, Dinh P, Rubens R, Gupta S. Pharmacodynamics, Efficacy, and Safety of IPX203 in Parkinson Disease Patients With Motor Fluctuations. Clin Neuropharmacol. 2019 Sep/Oct;42(5):149-156. doi: 10.1097/WNF.0000000000000354. PubMed 31306216 ↗
  • Hauser RA, Espay AJ, Ellenbogen AL, Fernandez HH, Isaacson SH, LeWitt PA, Ondo WG, Pahwa R, Schwarz J, Stocchi F, Zeitlin L, Banisadr G, Fisher S, Visser H, D'Souza R. IPX203 vs Immediate-Release Carbidopa-Levodopa for the Treatment of Motor Fluctuations in Parkinson Disease: The RISE-PD Randomized Clinical Trial. JAMA Neurol. 2023 Oct 1;80(10):1062-1069. doi: 10.1001/jamaneurol.2023.2679. PubMed 37578800 ↗
  • Hauser RA, Fernandez HH, Jimenez-Shahed J, Allard S, Banisadr G, Fisher S, D'Souza R. Duration of "Good On" time per dose: Immediate-release carbidopa-levodopa vs. extended-release carbidopa-levodopa (IPX203, CREXONT(R)). Parkinsonism Relat Disord. 2025 Feb;131:107239. doi: 10.1016/j.parkreldis.2024.107239. Epub 2024 Dec 15. PubMed 39733558 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Feb 2027, 18 months after the start.

Of 42 non-industry phase 4 interventional studies under Parkinson Disease, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 75. This study's planned 18 months is below that.

Counting every sponsor, half of 57 studies reached it within 28 months; a quarter within 19 and three quarters within 65.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 15, 2026: primary completion Dec 2026 → Feb 2027 and completion May 2027 → Jun 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2025
First posted
Aug 24, 2025
StartActual
Jul 24, 2025
Primary completionEst.
Feb 15, 2027was Dec 2026
CompletionEst.
Jun 15, 2027was May 2027
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 15, 2026→Feb 15, 2027
Oct 15, 2026
Study completion
May 15, 2027→Jun 15, 2027
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Primary completion Dec 15, 2026→Feb 15, 2027
    Study completion May 15, 2027→Jun 15, 2027
    + 2 other changes: verification date and responsible party

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07138560
Responsible party
Saar Anis (Movement Disorder Staff Physician, The Cleveland Clinic) — Principal investigator
First posted
Aug 24, 2025
Start date
Jul 24, 2025
Primary completion
Feb 15, 2027 (estimated)
Completion
Jun 15, 2027 (estimated)
Last update
Oct 15, 2026

Study contacts

Saar Anis, MD
Contact
ANISS2@ccf.org
216 678-8896
Mary Carmell Beukemann
Contact
beukemm@ccf.org
216-372-2867
Hubert Fernandez, MD
principal investigator · The Cleveland Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: IPX203

Start the discussion